ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 140 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.08 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $762 | -89.3% | 80 | -83.3% | 0.00% | – |
Q4 2022 | $7,104 | +610.4% | 480 | +823.1% | 0.00% | – |
Q3 2022 | $1,000 | -83.3% | 52 | -81.8% | 0.00% | – |
Q2 2022 | $6,000 | +20.0% | 285 | 0.0% | 0.00% | – |
Q1 2022 | $5,000 | +66.7% | 285 | +150.0% | 0.00% | – |
Q3 2021 | $3,000 | 0.0% | 114 | +23.9% | 0.00% | – |
Q2 2021 | $3,000 | – | 92 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
FRAZIER MANAGEMENT LLC | 10,542,790 | $296,569,000 | 22.84% |
Bain Capital Life Sciences Investors, LLC | 3,979,292 | $111,937,000 | 7.03% |
Pivotal bioVenture Partners Investment Advisor LLC | 671,716 | $18,895,000 | 6.23% |
Omega Fund Management, LLC | 640,199 | $18,009,000 | 2.70% |
Orbimed Advisors | 6,073,850 | $170,857,000 | 1.50% |
Vivo Capital, LLC | 867,170 | $24,393,000 | 1.09% |
Octagon Capital Advisors LP | 100,000 | $2,813,000 | 0.98% |
Altium Capital Management LP | 62,962 | $1,771,000 | 0.66% |
RA Capital Management | 1,165,184 | $32,777,000 | 0.46% |
SILVERARC CAPITAL MANAGEMENT, LLC | 8,505 | $239,000 | 0.14% |